Lactams
Medchemexpress LLC Tz-thalidomide | 2087490-42-2 | 98.6% | 571.58 | C29H29N7O6 | 10 MG
Tz-Thalidomide is a tetrazine-tagged derivative of thalidomide used in degrader and click-chemistry research. It serves as an E3 ligase ligand and contains a tetrazine group capable of undergoing inverse electron-demand Diels-Alder (iEDDA) reactions with trans-cyclooctene (TCO) partners. Reported biochemical data indicate binding affinity for BRD4. Typical purity is 98.6% and the compound is supplied as a solid and as a 10 mM solution in DMSO.
Medchemexpress LLC CD3 epsilon 1-27 pep 20ug | 20ug
CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling When APC activates the TCR CD3 epsilon together with CD3D CD3G and CD3Z transmits signals across the cell membrane through ITAMs CD3 epsilon 1-27 peptide Protein Human (Biotinylated HEK293 hFc-Avi) is the recombinant human-derived CD3 epsilon 1-27 peptide protein expressed by HEK293 with C-Avi C-hFc labeled tag
Medchemexpress LLC Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride | 2376990-30-4 | 498.91 | 50 MG
Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride incorporates an E3 ligase ligand and a linker, and can be an immunomodulator for the treatment of cancer. PROTACs, which contain two different ligands connected by a linker (one for an E3 ubiquitin ligase and the other for the target protein), exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
- Incorporates an E3 ligase ligand and a linker.
- Can be an immunomodulator for the treatment of cancer.
- Exploits the intracellular ubiquitin-proteasome system.
- Selectively degrades target proteins.
- For research use only.
Medchemexpress LLC Thalidomide-o-amido-peg3-c2-nh2 (TFA) | 1957236-21-3 | MFCD31656717 | 99.6% | 620.53 g/mol | C25H31F3N4O11 | 50 MG
Thalidomide-O-amido-PEG3-C2-NH2 TFA is a Thalidomide-based cereblon E3 ligase ligand-linker conjugate provided as the trifluoroacetate salt. It contains a three-unit polyethylene glycol (PEG3) linker and a terminal C2 primary amine for conjugation, and is intended as a building block for PROTAC synthesis and cereblon recruitment studies.
- Cereblon-binding thalidomide ligand with a three-unit PEG linker.
- Terminal primary amine (C2) for facile conjugation to targeting ligands.
- Provided as a trifluoroacetate (TFA) salt for handling stability.
- High purity confirmed by LCMS (~99.6%).
- Molecular weight 620.53 g/mol and CAS 1957236-21-3 for unambiguous identification.
Medchemexpress LLC Thalidomide-O-C8-Boc | 2225148-52-5 | MFCD32701934 | 95.1% | 486.56 g·mol⁻¹ | C26H34N2O7 | 5 MG
Thalidomide-O-C8-Boc is a thalidomide-derived Cereblon (CRBN) ligand for targeted protein degradation research. It is designed to be connected to a protein-targeting ligand via a linker to form PROTAC molecules and is provided as a research-grade chemical with manufacturer-reported purity (~95.1%).
- Acts as a cereblon ligand to recruit CRBN.
- Designed for conjugation via a linker to form PROTACs.
- Supplied at research-grade purity (~95.1%).
- Molecular formula C26H34N2O7; molecular weight 486.56 g·mol⁻¹.
- Available in milligram-scale quantities suitable for synthesis and screening.
Medchemexpress LLC (S)-thalidomide | 841-67-8 | MFCD00210219 | 99.5% | C13H10N2O4 | 10MG
(S)-Thalidomide is the S-enantiomer of thalidomide, a small-molecule ligand of the E3 ubiquitin ligase substrate receptor cereblon (CRBN). It exhibits immunomodulatory, anti-inflammatory, antiangiogenic, and pro-apoptotic activities and is used as a research reagent to study CRBN-mediated degradation pathways and molecular glue mechanisms. For research use only.
- High chemical purity suitable for analytical and biological studies.
- Known to bind cereblon and induce substrate recruitment for degradation.
- Useful in studies of immunomodulation, angiogenesis, and apoptosis.
- Available in small milligram pack sizes for screening and synthesis.
- Provided with manufacturer documentation including SDS and COA.
Medchemexpress LLC Thalidomide-O-amido-C8-NH2 (TFA) | 1950635-16-1 | MFCD31560485 | >=95.0% | 572.53 g/mol | C25H31F3N4O8 | 25 MG
Thalidomide-O-amido-C8-NH2 (TFA) is a thalidomide-derived cereblon ligand-linker conjugate supplied as the trifluoroacetic acid salt. It is intended for use as a building block in PROTAC synthesis and other E3 ligase ligand-linker research in chemical biology.
- Chemical form: TFA salt.
- Chemical formula: C25H31F3N4O8.
- CAS number: 1950635-16-1.
- Molecular weight: 572.53 g/mol.
- Appearance: solid.
- Typical use: building block for PROTAC and E3 ligase ligand-linker conjugate synthesis.
- Purity: high (≥95%).
Medchemexpress LLC Thalidomide-O-amido-C3-PEG3-C1-NH2 | 1799711-29-7 | 99.1% | 648.58 g/mol | C27H35F3N4O11 | 5 MG
Thalidomide-O-amido-C3-PEG3-C1-NH2 is a thalidomide-derived cereblon E3 ligase ligand conjugated to a three-unit PEG linker and a short C3 spacer terminating in an amine. Supplied for research use, it is intended as a linker-ligand building block for PROTAC design and related chemical biology applications.
- Thalidomide-based cereblon ligand for E3 ligase recruitment.
- Three-unit PEG linker and C3 spacer terminating in an amine for conjugation.
- High purity suitable for research applications (~99.1%).
- Available in small pack sizes for discovery work (mg scale).
- Store sealed at 4°C; in solution store at -80°C (6 months) or -20°C (1 month).
- For research use only, not for human use.
![eMolecules Broadpharm / D-acid-PEG4-Thalidomide-5-(PEG4-acid) / 100mg / 779524498 / BP-29724 / 98.000 / / [null] / 770.782 / C35H50N2O17](https://assets.fishersci.com/TFS-Assets/CCG/product-images/502473531.JPG-250.jpg)
eMolecules Broadpharm / D-acid-PEG4-Thalidomide-5-(PEG4-acid) / 100mg / 779524498 / BP-29724 / 98.000 / / [null] / 770.782 / C35H50N2O17
Broadpharm / D-acid-PEG4-Thalidomide-5-(PEG4-acid) / 100mg / 779524498 / BP-29724 / 98.000 / / [null] / 770.782 / C35H50N2O17
Medchemexpress LLC Thalidomide-O-amido-PEG2-C2-NH2 (TFA) | 1957235-75-4 | 576.48 | 50 MG
Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide-based cereblon ligand and a 2-unit PEG linker used in PROTAC technology. This product is intended for research use only and for experienced personnel in appropriately equipped facilities.
- Incorporates Thalidomide-based cereblon ligand
- Features a 2-unit PEG linker
- Used in PROTAC technology
- PROTACs exploit the intracellular ubiquitin-proteasome system
- Selectively degrades target proteins
- Identified as laboratory chemicals for substance manufacture
Medchemexpress LLC Thalidomide-5-peg2-cl | 2230956-57-5 | 96.6% | C17H17ClN2O6 | 10MG
Thalidomide-5-PEG2-Cl is a thalidomide-derived cereblon (CRBN) ligand featuring a short PEG2 spacer and a terminal chloride. It is supplied as a research-grade building block for conjugation in PROTAC design and other CRBN-targeting chemical biology applications, with documented molecular formula and purity.
- Provides a CRBN-recruiting moiety suitable for PROTAC assembly.
- Contains a PEG2 linker for flexible conjugation to ligands.
- Terminal chloride enables straightforward chemical derivatization.
- Supplied with referenced purity and characterization data.
- Available in small research-friendly pack sizes for early-stage work.
![Chemscene ChemScene | tert-Butyl 6-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate | 250MG | CS-0088547 | 0.98 | 208837-83-6| MFCD09040607 | 198.26](https://assets.fishersci.com/TFS-Assets/CCG/product-images/CS-0088547.JPG-250.jpg)
Chemscene ChemScene | tert-Butyl 6-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate | 250MG | CS-0088547 | 0.98 | 208837-83-6| MFCD09040607 | 198.26
ChemScene | tert-Butyl 6-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate | 250MG | CS-0088547 | 0.98 | 208837-83-6| MFCD09040607 | 198.26
Medchemexpress LLC Thalidomide-5-PEG4-NH2 hydrochloride | 2743434-24-2 | 95.2% | C21H28ClN3O8 | 10MG
Thalidomide-5-PEG4-NH2 hydrochloride is a thalidomide-derived cereblon ligand conjugated to a PEG4 linker and supplied as the hydrochloride salt. It serves as an E3 ligase ligand-linker building block for PROTAC design and related chemical biology research.
- Incorporates thalidomide-based cereblon ligand for E3 ligase recruitment.
- PEG4 linker provides a flexible spacer for bifunctional molecule design.
- Hydrochloride salt form improves handling and solubility properties.
- Intended for use in proteolysis-targeting chimera (PROTAC) synthesis.
- Molecular weight 485.92 g/mol; chemical formula C21H28ClN3O8.
- Manufacturer-reported purity 95.2% suitable for research applications.
Medchemexpress LLC Thalidomide | 50-35-1 | MFCD00153873 | 100.0% | C13H10N2O4 | 10MG
Thalidomide (analytical standard) is a high-purity reference compound (CAS 50-35-1) intended for research and analytical applications. It serves as a cereblon inhibitor standard for assay calibration, method development, and reference testing. Consult the certificate of analysis and safety data sheet for batch-specific purity and handling instructions.
- High purity (99.96%) suitable for analytical standards.
- Provided in small, laboratory-scale quantities for method development.
- Supplied with certificate of analysis and safety data sheet.
- Intended for research and analytical use only.
- Suitable for assays targeting cereblon-related activity.
Medchemexpress LLC Thalidomide-NH-PEG1-NH2 hydrochloride | 2154342-56-8 | 99.2% | C17H21ClN4O5 | 10MG
Thalidomide-NH-PEG1-NH2 hydrochloride is a thalidomide-derived cereblon E3 ligase ligand-linker conjugate supplied as the hydrochloride salt and intended as a building block for PROTAC design and small-molecule degradation strategies. It couples a cereblon-recruiting moiety with a short PEG1 diamine linker to facilitate conjugation to target-binding ligands and streamline synthesis workflows.
- Provides thalidomide-based cereblon recruiting moiety.
- Includes a short PEG1 diamine linker for flexibility in conjugation.
- Supplied as hydrochloride salt for improved stability and handling.
- High purity suitable for synthetic applications (99.2%).
- Available in small milligram quantities for early-stage research.